Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
103 pending office actions • 45 art units • 93 examiners • 1 of 103 (1%) have an AI response strategy ready • 77 patents granted in the last 365 days
Genentech Inc. is managing 104 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 94 distinct examiners, indicating very little examiner overlap within the current pending set. The portfolio is active in 45 distinct art units, reflecting a wide range of biotechnological innovations being reviewed by the USPTO.
NGUYEN, TUAN HOANG is the busiest examiner for the company, overseeing 2 pending office actions. With 104 total pending office actions and 94 distinct examiners, the prosecution team must address many unique examiner perspectives. The involvement of 45 distinct art units suggests that the company's work is technically diverse, requiring the legal team to be familiar with the practices of many different specialized groups. This distribution requires a prosecution strategy that is highly adaptable to the different technical standards and examiner preferences found across 45 different art units in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 31 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 31 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 11 (11%) |
| §103 only | 30 (29%) |
| §102 only | 5 (5%) |
| §112 only | 12 (12%) |
| Double-patenting only | 2 (2%) |
| Double-patenting + other | 14 (14%) |
| Multi-statute (no §101) | 26 (25%) |
| No statute on record | 2 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, TUAN HOANG | 2 | 90.5% | +4.0% |
| GUSTILO, ESTELLA M | 2 | 53.6% | +34.5% |
| RODRIGUEZ, RAYNA B | 2 | 33.6% | +19.2% |
| BELYAVSKYI, MICHAIL A | 2 | 64.2% | +27.6% |
| KIM, YUNSOO | 2 | 65.9% | +34.3% |
| JARRETT, LORE RAMILLANO | 2 | 68.5% | +25.1% |
| HOANG, HAN DINH | 2 | 75.0% | +17.7% |
| GAO, ASHLEY HARTMAN | 2 | 56.7% | +38.2% |
| GODDARD, LAURA B | 2 | 50.9% | +13.5% |
| BOESEN, CHRISTIAN C | 2 | 75.9% | +21.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18911076 | ANOMALY DETECTION IN MEDICAL IMAGING DATA | NGUYEN, TUAN HOANG | — |
| 18909867 | PATHOLOGICAL RESPONSE CALCULATION AND ASSESSMENT TOOL | NGUYEN, TUAN HOANG | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17378651 | ATTENTION-BASED NEURAL NETWORK TO PREDICT PEPTIDE BINDING, PRESENTATION, AND IMMUNOGENICITY | BAILEY, STEVEN WILLIAM | 396d overdue |
| 17964325 | METHOD FOR MEDIUM TREATMENT BEFORE INOCULATION | MOSS, NATALIE M | 127d overdue |
| 18523284 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | SHIAO, REI TSANG | 91d overdue |
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | GODDARD, LAURA B | 84d overdue |
| 17075238 | OVERLOAD AND ELUTE CHROMATOGRAPHY | STONEBRAKER, ALYSSA RAE | 72d overdue |
| 18315450 | SMALL PARTS CLEANING APPARATUS AND METHODS OF USE | LEE, KEVIN G | 58d overdue |
| 17172528 | CELL CULTURE STRATEGIES FOR MODULATING PROTEIN GLYCOSYLATION | AFREMOVA, VERA | 49d overdue |
| 18627251 | BIOLOGICAL CONTEXT FOR ANALYZING WHOLE SLIDE IMAGES | ROSARIO, DENNIS | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | GODDARD, LAURA B | 84d overdue |
| 18048986 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES | GODDARD, LAURA B | 10d overdue |
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | GUSTILO, ESTELLA M | — |
| 18785844 | CDK INHIBITORS | RODRIGUEZ, RAYNA B | — |
| 18651221 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | BELYAVSKYI, MICHAIL A | — |
| 18636947 | CELL-BASED ASSAY FOR DETECTING ANTl-CD3 HOMODIMERS | BELYAVSKYI, MICHAIL A | — |
| 18600194 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | KIM, YUNSOO | — |
| 18416031 | Anti-Jagged1 Antibodies and Methods of Use | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 1644 | 5 |
| 1646 | 4 |
| 1642 | 4 |
| 1687 | 4 |
| 1641 | 3 |
| 1678 | 3 |
| 2661 | 3 |
| 1643 | 3 |
| 1635 | 2 |
| 1621 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19409123 | CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION | TAYLOR, LIA ELAN | 1641 | §103 | Final Rejection | — | Pending | Dec 04, 2025 |
| 19029418 | DEEP LEARNING FOR NEW AND ENLARGING LESIONS | USTARIS, JOSEPH G | — | §103 | Non-Final OA | — | Pending | Jan 17, 2025 |
| 18981116 | DETECTING LONGITUDINAL PROGRESSION OF ALZHEIMER'S DISEASE (AD) BASED ON SPEECH ANALYSES | SAINT CYR, LEONARD | — | §103 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18981081 | MICROSCOPE SLIDE IMAGE-BASED MACHINE LEARNING IMAGE ANALYSIS FOR INFLAMMATORY BOWEL DISEASE | SALEH, ZAID MUHAMMAD | — | §102§103 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18939497 | MACHINE LEARNING ENABLED DIAGNOSIS AND LESION LOCALIZATION FOR NASCENT GEOGRAPHIC ATROPHY IN AGE-RELATED MACULAR DEGENERATION | YANG, WEI WEN | — | §102§103 | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18933358 | BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | HALVORSON, MARK | 1646 | §103Other | Non-Final OA | — | Pending | Oct 31, 2024 |
| 18929474 | MACHINE LEARNING ENABLED HEPATOCELLULAR CARCINOMA MOLECULAR SUBTYPE CLASSIFICATION | DHOOGE, DEVIN J | — | §103 | Non-Final OA | — | Pending | Oct 28, 2024 |
| 18859952 | DRUG PRODUCTION METHOD | GAVIN, KRISTIN ELIZABETH | 3624 | §101§103 | Non-Final OA | 40d | Pending | Oct 24, 2024 |
| 18859397 | SOLID FORM OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3- FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9- TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL TARTRATE | WELLS, LAUREN QUINLAN | — | §103§112DP | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18911076 | ANOMALY DETECTION IN MEDICAL IMAGING DATA | NGUYEN, TUAN HOANG | — | DP | Non-Final OA | — | Pending | Oct 09, 2024 |
| 18909867 | PATHOLOGICAL RESPONSE CALCULATION AND ASSESSMENT TOOL | NGUYEN, TUAN HOANG | — | §103Other | Non-Final OA | — | Pending | Oct 08, 2024 |
| 18846553 | DETERMINING A PATIENT’S RESPONSE TO A TREATMENT IN MULTIPLE MYELOMA | LEE, ANDREW ELDRIDGE | 3684 | §101§103 | Final Rejection | — | Pending | Sep 12, 2024 |
| 18820925 | PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA | MOEHLMAN, ANDREW TERRY | 1655 | §112 | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18817828 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING AN ATP COMPETITIVE AKT INHIBITOR, A CDK4/6 INHIBITOR, AND FULVESTRANT | KOSTURKO, GEORGE W | — | §102§103DP | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | GUSTILO, ESTELLA M | 1646 | §102§103§112Other | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18793023 | DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BRUTON'S TYROSINE KINASE | HOWELL, THEODORE R | — | §103DP | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18785844 | CDK INHIBITORS | RODRIGUEZ, RAYNA B | — | §112Other | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18771363 | OVARIAN TOXICITY ASSESSMENT IN HISTOPATHOLOGICAL IMAGES USING DEEP LEARNING | NGUYEN, KHAI MINH | — | §103Other | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18752501 | MULTI-VECTOR RECOMBINASE MEDIATED CASSETTE EXCHANGE | KONOPKA, CATHERINE ANNE | 1635 | §103§112DP | Non-Final OA | 78d overdue | Pending | Jun 24, 2024 |
| 18734329 | SOLID FORMULATIONS COMPRISING AN INHIBITOR OF THE K-RAS PROTEIN HAVING A G12C MUTATION, AND A PROCESS FOR PREPARING | PALLAY, MICHAEL B | 1617 | §103§112 | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18668774 | METHODS OF TREATING CANCER WITH PI3K INHIBITOR, GDC-0077 | BAEK, BONG-SOOK | 1611 | §103Other | Non-Final OA | — | Pending | May 20, 2024 |
| 18669218 | SYNTHETIC CONTROLS FOR IMMUNOHISTOCHEMISTRY | NGUYEN, NAM P | 1678 | §103 | Non-Final OA | 22d overdue | Pending | May 20, 2024 |
| 18710130 | BRM DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | MCKOY, QUINCY ANDRE | — | §102§112 | Non-Final OA | — | Pending | May 14, 2024 |
| 18651221 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | BELYAVSKYI, MICHAIL A | — | §102 | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18642305 | HIGH-THROUGHPUT METHODS FOR PREPARING LIPID NANOPARTICLES AND USES THEREOF | MITCHELL, EDWIN COLEMAN | 1619 | §102§103§112DP | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18636947 | CELL-BASED ASSAY FOR DETECTING ANTl-CD3 HOMODIMERS | BELYAVSKYI, MICHAIL A | 1644 | §102Other | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18627251 | BIOLOGICAL CONTEXT FOR ANALYZING WHOLE SLIDE IMAGES | ROSARIO, DENNIS | 2676 | §101§103 | Final Rejection | 31d overdue | Pending | Apr 04, 2024 |
| 18698664 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | MARTIN, KEVIN STEPHEN | 1624 | §102§103 | Final Rejection | — | Pending | Apr 04, 2024 |
| 18612141 | USES OF IL-13 ANTAGONISTS FOR TREATING ATOPIC DERMATITIS | CHATTIN, AMY MARIE | — | §103DP | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18611567 | DATA QUALITY CONTROL AND INTEGRATION FOR DIGITAL PATHOLOGY | RAJAPUTRA, SUMAN | 2172 | §101§103 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18604429 | METABOLOMIC ANALYSIS | FRITCHMAN, REBECCA M | — | §112 | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18600194 | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE | KIM, YUNSOO | — | §103DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18593665 | ION EXCHANGE MEMBRANE CHROMATOGRAPHY | PUTTLITZ, KARL J | 1644 | §112DP | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18587251 | METHODS OF TREATING TAU PATHOLOGIES | JUEDES, AMY E | — | §102DP | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18584311 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | YOO, SUN JAE | 1621 | §102 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18431838 | METHOD AND APPARATUS FOR BIOLOGICAL CELL HARVESTING | COOLEY, CHARLES E | — | §103 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18429055 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | MACFARLANE, STACEY NEE | — | §102§112DP | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18417787 | BRAIN TARGETING COMPOSITIONS AND METHODS OF USE THEREOF | BUTTICE, AUDREY L | 1647 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18416031 | Anti-Jagged1 Antibodies and Methods of Use | GUSTILO, ESTELLA M | — | §112DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18413682 | FC Variants and Methods for Their Production | DEBERRY, REGINA M | — | DP | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18412348 | AUTOMATED DIGITAL ASSESSMENT OF HISTOLOGIC SAMPLES | CRUZ, IRIANA | 2681 | §103 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18410827 | MINICOLUMN RETAINING APPARATUS AND METHOD OF USE | JARRETT, LORE RAMILLANO | — | §102§103 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18544236 | METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS | RODRIGUEZ, RAYNA B | 1628 | §103 | Final Rejection | — | Pending | Dec 18, 2023 |
| 18540310 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | DEKARSKE, MADELINE MCGUIRE | 1622 | §103§112 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18523284 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | SHIAO, REI TSANG | 1691 | §103§112 | Non-Final OA | 91d overdue | AI Ready | Nov 29, 2023 |
| 18516417 | TUMOR IMMUNOPHENOTYPING BASED ON SPATIAL DISTRIBUTION ANALYSIS | HOANG, HAN DINH | 2661 | §103 | Final Rejection | — | Pending | Nov 21, 2023 |
| 18516406 | DETECTING TERTIARY LYMPHOID STRUCTURES IN DIGITAL PATHOLOGY IMAGES | HOANG, HAN DINH | 2661 | §103 | Final Rejection | — | Pending | Nov 21, 2023 |
| 18516552 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | SCHMITT, MICHAEL J | 1629 | §103Other | Non-Final OA | 55d | Pending | Nov 21, 2023 |
| 18514280 | MODIFIED CELLS FOR THE PRODUCTION OF A RECOMBINANT PRODUCT OF INTEREST | MCKNIGHT, CIARA A | 1656 | §103§112 | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18510297 | COMBINED TRANSPOSON-MEDIATED INTEGRATION AND TARGETED INTEGRATION OF NUCLEIC ACIDS INTO HOST CELLS | MEYERING, SHABANA SHABBEER | 1635 | §103§112DP | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18504041 | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE | MOSELEY II, NELSON B | 1642 | Other | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18482237 | TREATMENT OUTCOME PREDICTION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION USING BASELINE CHARACTERISTICS | WINDSOR, COURTNEY J | 2661 | §103 | Non-Final OA | 31d overdue | Pending | Oct 06, 2023 |
| 18377039 | Traceable Medical Vials | AFRIFA-KYEI, ANTHONY D | 2686 | §103 | Final Rejection | — | Pending | Oct 05, 2023 |
| 18464580 | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE | SHUPE, ELIZABETH A | 1643 | §112 | Non-Final OA | 4d overdue | Pending | Sep 11, 2023 |
| 18463585 | ATTENTION-BASED MULTIPLE INSTANCE LEARNING FOR WHOLE SLIDE IMAGES | TRAN, DUY ANH | 2674 | §102 | Non-Final OA | 13d | Pending | Sep 08, 2023 |
| 18464135 | PREDICTION OF DISTRIBUTION OF GLYCANS ATTACHED TO MOLECULES MANUFACTURED IN A CELL CULTURE | STUBBS, JOHN THOMAS | — | §101§102§103§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18463118 | ESTIMATING HLA EXPRESSION LOSS | AUGER, NOAH ANDREW | — | §101§103§112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18449793 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND ABEMACICLIB OR RIBOCICLIB | CHAO, ALLEN | 1622 | §103 | Non-Final OA | — | Pending | Aug 15, 2023 |
| 18447986 | ESTIMATION OF MECHANISTIC CHROMATOGRAPHY MODEL UNCERTAINTY | GEBRESILASSIE, KIBROM K | — | §101§102 | Non-Final OA | — | Pending | Aug 10, 2023 |
| 18363155 | Multispecific Binding Protein Degrader Platform and Methods of Use | MELCHIOR, JAMES RYLAND | 1644 | §102§103§112Other | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18210604 | ASSEMBLY OF BISPECIFIC ANTIBODIES | HUYNH, PHUONG N | 1641 | Other | Final Rejection | 111d overdue | Pending | Jun 15, 2023 |
| 18334531 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | OUSPENSKI, ILIA I | 1644 | §103§112Other | Non-Final OA | 28d | Pending | Jun 14, 2023 |
| 18329972 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS | SITTON, JEHANNE SOUAYA | 1682 | §103 | Final Rejection | 52d overdue | Pending | Jun 06, 2023 |
| 18204281 | INDUCTIVE HEAT STERILIZING SYSTEMS, DEVICES, AND METHODS | LEE, AHAM NMN | 1758 | §103 | Final Rejection | 14d | Pending | May 31, 2023 |
| 18324406 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §112 | Non-Final OA | — | Pending | May 26, 2023 |
| 18201904 | METHODS FOR PREPARING MAMMALIAN CELLS FOR PERFUSION CELL CULTURE | MONTANARI, DAVID A | 1632 | §102§103 | Non-Final OA | — | Pending | May 25, 2023 |
| 18323240 | PYRROLIDINE DERIVATIVES AND METHODS OF USE | BELL, SARA ELIZABETH | 1625 | §112 | Final Rejection | 34d | Pending | May 24, 2023 |
| 18319618 | Reusable Cartridges for Detecting Analytes in Solution | MONTGOMERY, ANN Y | 1678 | §112 | Non-Final OA | — | Pending | May 18, 2023 |
| 18315450 | SMALL PARTS CLEANING APPARATUS AND METHODS OF USE | LEE, KEVIN G | 1711 | §103§112 | Final Rejection | 58d overdue | Pending | May 10, 2023 |
| 18195134 | 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER | WILSON, JERICA KATLYNN | 1621 | §103 | Non-Final OA | — | Pending | May 09, 2023 |
| 18309003 | RECOMBINANT PROTEINS FOR QUANTIFICATION OF PROTEIN LEVELS | NOAKES, SUZANNE MARIE | 1656 | §112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18295539 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 26d overdue | Pending | Apr 04, 2023 |
| 18194542 | HYDROXYPROPYL METHYL CELLULOSE DERIVATIVES TO STABILIZE POLYPEPTIDES | HARTLEY, MICHAEL G | 1614 | §103 | Non-Final OA | — | Pending | Mar 31, 2023 |
| 18190697 | THERMAL SEPARATOR APPARATUS FOR FLASK STIRRER AND METHOD OF USE | JARRETT, LORE RAMILLANO | 1797 | §103§112 | Final Rejection | — | Pending | Mar 27, 2023 |
| 18124096 | PURIFICATION OF MULTISPECIFIC ANTIBODIES | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | 10d overdue | Pending | Mar 21, 2023 |
| 18174889 | METHODS FOR PRODUCING ANTIBODIES | HOWARD, ZACHARY C | 1674 | §103§112 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18173673 | POINT OF CARE DRUG DELIVERY APPARATUS AND METHOD | STIGELL, THEODORE J | 3783 | §102§103 | Final Rejection | — | Pending | Feb 23, 2023 |
| 18173002 | ASSAYS AND REAGENTS FOR CHARACTERIZATION OF MHCI PEPTIDE BINDING | LUSI, ELLIS FOLLETT | 1677 | §103§112 | Final Rejection | 21d | Pending | Feb 22, 2023 |
| 18104825 | T CELL-BASED METHODS FOR PREDICTING POLYPEPTIDE IMMUNOGENICITY | GAO, ASHLEY HARTMAN | 1600 | §103 | Non-Final OA | — | Pending | Feb 02, 2023 |
| 18156744 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | VAN DRUFF, SYDNEY | 1643 | §103DP | Final Rejection | 53d overdue | Pending | Jan 19, 2023 |
| 18089335 | SUPRACHOROIDAL INJECTION DEVICE | PRICE, NATHAN R | 3783 | §102§103 | Non-Final OA | — | Pending | Dec 27, 2022 |
| 18048986 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES | GODDARD, LAURA B | 1642 | §103 | Final Rejection | 10d overdue | Pending | Oct 24, 2022 |
| 18046865 | METHODS FOR ASSAYING T-CELL DEPENDENT BISPECIFIC ANTIBODIES | SKELDING, ZACHARY S | 1644 | §103DP | Final Rejection | 12d | Pending | Oct 14, 2022 |
| 17965363 | Method for Enriching Extracellular Vesicles From Biological Fluid Samples | BOESEN, CHRISTIAN C | 1684 | §102 | Non-Final OA | — | Pending | Oct 13, 2022 |
| 17964325 | METHOD FOR MEDIUM TREATMENT BEFORE INOCULATION | MOSS, NATALIE M | 1653 | §103§112 | Non-Final OA | 127d overdue | Pending | Oct 12, 2022 |
| 17947820 | USE OF GENETIC ALGORITHMS TO DETERMINE A MODEL TO IDENTITY SAMPLE PROPERTIES BASED ON RAMAN SPECTRA | THOMPSON, MILANA KAYE | 1687 | §103 | Final Rejection | — | Pending | Sep 19, 2022 |
| 17932885 | SYSTEMS AND METHODS TO TRACK THE EVOLUTION OF SINGLE CELLS | BOESEN, CHRISTIAN C | 1684 | §101§102§112 | Non-Final OA | — | Pending | Sep 16, 2022 |
| 17822746 | EFFICIENT GENOME EDITING IN PRIMARY MYELOID CELLS | VANHORN, ABIGAIL LOUISE | 1636 | §103 | Final Rejection | 87d overdue | Pending | Aug 26, 2022 |
| 17842715 | CULTURE SYSTEM AND METHODS FOR IMPROVED MODELING OF NEUROLOGICAL CONDITIONS | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | 37d overdue | Pending | Jun 16, 2022 |
| 17833719 | METHODS, SYSTEMS, AND TOOLS FOR LONGEVITY-RELATED APPLICATIONS | BEVERIDGE, CONNOR HAMMOND | 1687 | §101§103 | Non-Final OA | — | Pending | Jun 06, 2022 |
| 17587760 | PREDICTION OF SIDE-CHAIN DEGRADATION IN POLYMERS THROUGH PHYSICS BASED SIMULATIONS | LIU, GUOZHEN | 1686 | §101§103DP | Final Rejection | — | Pending | Jan 28, 2022 |
| 17643623 | QUINAZOLINYL COMPOUNDS AND METHODS OF USE | HIRAKIS, SOPHIA P | 1623 | §112 | Non-Final OA | — | Pending | Dec 10, 2021 |
| 17542138 | METHOD FOR REGENERATION OF AN OVERLOAD CHROMATOGRAPHY COLUMN | KIM, YUNSOO | 1641 | §103 | Final Rejection | — | Pending | Dec 03, 2021 |
| 17503122 | ANTIBODY POTENCY ASSAY | EVANS, CHRISTOPHER RYAN | 1677 | §103 | Final Rejection | 1d overdue | Pending | Oct 15, 2021 |
| 17473401 | TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB | CHASE, CAROL ANN | 1646 | §103§112 | Final Rejection | 4d overdue | Pending | Sep 13, 2021 |
| 17383316 | METHOD FOR THE EXPRESSION OF AN ANTIBODY-MULTIMER-FUSION | MIDDLETON, DANAYA L | 1674 | §112Other | Non-Final OA | — | Pending | Jul 22, 2021 |
| 17378651 | ATTENTION-BASED NEURAL NETWORK TO PREDICT PEPTIDE BINDING, PRESENTATION, AND IMMUNOGENICITY | BAILEY, STEVEN WILLIAM | 1687 | §101 | Final Rejection | 396d overdue | Pending | Jul 16, 2021 |
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | GODDARD, LAURA B | 1642 | §103§112Other | Non-Final OA | 84d overdue | Pending | Jun 18, 2021 |
| 17229746 | COPPER LOSS MITIGATION | MIANO, JOSEPH PAUL | 1631 | §102§103§112 | Final Rejection | 9d | Pending | Apr 13, 2021 |
| 17172528 | CELL CULTURE STRATEGIES FOR MODULATING PROTEIN GLYCOSYLATION | AFREMOVA, VERA | 1653 | §102§103§112 | Non-Final OA | 49d overdue | Pending | Feb 10, 2021 |
| 17168621 | USE OF TRYPTOPHAN DERIVATIVES AND L-METHIONINE FOR PROTEIN FORMULATION | GAO, ASHLEY HARTMAN | 1678 | §103Other | Final Rejection | — | Pending | Feb 05, 2021 |
| 17075238 | OVERLOAD AND ELUTE CHROMATOGRAPHY | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Final Rejection | 72d overdue | Pending | Oct 20, 2020 |
| 16115373 | METHODS AND SYSTEMS FOR EVALUATING TUMOR MUTATIONAL BURDEN | WOITACH, JOSEPH T | 1687 | §101§112 | Final Rejection | — | Pending | Aug 28, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial